Baillie Gifford & Co. Reduces Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Baillie Gifford & Co. trimmed its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 71.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 121,855 shares of the company’s stock after selling 308,742 shares during the period. Baillie Gifford & Co. owned 0.20% of Health Catalyst worth $992,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Summit Global Investments raised its holdings in Health Catalyst by 8.1% in the 3rd quarter. Summit Global Investments now owns 66,544 shares of the company’s stock valued at $542,000 after acquiring an additional 4,991 shares during the last quarter. Impax Asset Management Group plc raised its holdings in shares of Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after acquiring an additional 360,201 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of Health Catalyst by 21.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after acquiring an additional 2,064 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Health Catalyst in the third quarter valued at about $897,000. Finally, Nepsis Inc. increased its position in Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after purchasing an additional 851,448 shares during the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on HCAT. Stephens decreased their target price on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Royal Bank of Canada upped their price objective on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Piper Sandler cut their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Evercore ISI upped their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Citigroup raised their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.54.

Insider Activity

In related news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is currently owned by company insiders.

Health Catalyst Stock Up 6.5 %

Shares of HCAT opened at $8.66 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market capitalization of $526.96 million, a PE ratio of -6.55 and a beta of 1.32. The company’s 50-day simple moving average is $8.11 and its 200-day simple moving average is $7.19. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.22) EPS. Analysts forecast that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.